A Financing 858 Therapeutics Launches with Proven Team and …

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing-- Serial entrepreneurs Jeff Stafford, Jim Veal, Gretchen Bain form another San Diego-based discovery …

CouponFollow Extension

$60
OFF

A Financing 858 Therapeutics Launches With Proven Team And …

6 days from now

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing-- Serial entrepreneurs Jeff Stafford, Jim Veal, Gretchen Bain form another San Diego-based discovery …

versantventures.com

$60
OFF

News | 858 Therapeutics Launches With Proven Team And $60 …

6 days from now

Sep 21, 2021 858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

versantventures.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million

6 days from now

Sep 21, 2021 · 858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures 858 Therapeutics Launches with Proven Team and …

biospace.com

$60
OFF

San Diego Biotech Uncloaks With $60 Million To Tackle Treatment ...

6 days from now

Sep 21, 2021 · A San Diego-based biotech has exited stealth mode with hopes of treating cancers that are resistant to current therapies. On Tuesday, 858 Therapeutics launched with a …

biospace.com

$60
OFF

381 Investments, Portfolio, Team Members - Unicorn Nest

6 days from now

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing – 858 Therapeutics has raised $60m in Series A financing. – The round was led by founding investor …

unicorn-nest.com

$60
OFF

NEA — 14 Investments, Portfolio, Team Members - Unicorn Nest

6 days from now

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing – 858 Therapeutics has raised $60m in Series A financing. – The round was led by founding investor …

unicorn-nest.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million …

6 days from now

SAN DIEGO--(BUSINESS WIRE)-- 858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, …

creditriskmonitor.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million …

6 days from now

On September 21, 2021 858 Therapeutics reported that stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant …

1stoncology.com

$60
OFF

Series A - 858 Therapeutics - 2021-09-21 - Crunchbase

6 days from now

Sep 21, 2021 · News — 858 Therapeutics Launches with Proven Team and $60 Million Series A Financing . ... Business Wire — 858 Therapeutics Launches with Proven Team and $60 …

crunchbase.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million

6 days from now

Sep 21, 2021 · SAN DIEGO--(BUSINESS WIRE)--858 Therapeutics, Inc. today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with …

biospace.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million …

6 days from now

Sep 21, 2021 · Share this Story : 858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

financialpost.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million …

6 days from now

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing . ... With this financing, the company plans to expand its team to about 40 people within the next 18 months. …

preipopharma.com

FAQs about A Financing 858 Therapeutics Launches with Proven Team and … Coupon?

What is 858 Therapeutics?

858 Therapeutics is a biotech startup that has formally launched after operating in stealth for more than 2 years. They have secured $60 million in series A financing to develop small-molecule drugs for cancer. Their initial focus is on RNA-modifying enzymes and innate immunity. ...

Who backed 858?

The round was led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital. – 858 is a biotechnology company developing novel therapeutics for the treatment of cancer. ...

Who are the founders of 858?

858’s founding team includes CEO Jeffrey Stafford, Ph.D., CSO James Veal, Ph.D., and VP of Biology Gretchen Bain, Ph.D. They previously held leadership roles at three other San Diego-based discovery companies co-founded by Versant including Jecure Therapeutics, Quanticel Pharmaceuticals and Amira Pharmaceuticals. ...

What is a series a grant for 858?

The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies. 858 is headquartered in San Diego and will maintain lab operations both in San Diego and New York City. ...

Will funding help 858's METTL3 program in 2023?

The financing for 858 Therapeutics should help advance their lead programs, including the METTL3 program from Gotham, into the clinic by 2023.\nStafford says... Gotham was based on the work of its cofounder Samie Jaffrey, a scientist at Weill Cornell Medicine. Jaffrey is now an advisor to 858. ...

Has 858 Therapeutics acquired Gotham Therapeutics?

858 Therapeutics has acquired Gotham Therapeutics, based in New York City, for an undisclosed sum. Gotham is focused on epitranscriptomics, the study of chemical modifications of RNA. In addition to its own drug discovery programs, 858’s pipeline will get a boost through this acquisition. ...